- Home
- JWEL vs PALI Comparison
JWEL vs PALI Comparison
Compare JWEL & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- PALI
- Stock Information
- Founded
- JWEL 2012
- PALI 1996
- Country
- JWEL China
- PALI United States
- Employees
- JWEL N/A
- PALI N/A
- Industry
- JWEL Other Consumer Services
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JWEL Consumer Discretionary
- PALI Health Care
- Exchange
- JWEL Nasdaq
- PALI Nasdaq
- Market Cap
- JWEL 3.8M
- PALI 3.2M
- IPO Year
- JWEL 2021
- PALI N/A
- Fundamental
- Price
- JWEL $1.98
- PALI $0.76
- Analyst Decision
- JWEL
- PALI Strong Buy
- Analyst Count
- JWEL 0
- PALI 2
- Target Price
- JWEL N/A
- PALI $12.00
- AVG Volume (30 Days)
- JWEL 8.2K
- PALI 460.4K
- Earning Date
- JWEL 06-10-2025
- PALI 05-12-2025
- Dividend Yield
- JWEL N/A
- PALI N/A
- EPS Growth
- JWEL N/A
- PALI N/A
- EPS
- JWEL N/A
- PALI N/A
- Revenue
- JWEL $132,981,531.00
- PALI N/A
- Revenue This Year
- JWEL N/A
- PALI N/A
- Revenue Next Year
- JWEL N/A
- PALI N/A
- P/E Ratio
- JWEL N/A
- PALI N/A
- Revenue Growth
- JWEL N/A
- PALI N/A
- 52 Week Low
- JWEL $1.06
- PALI $0.60
- 52 Week High
- JWEL $3.71
- PALI $5.15
- Technical
- Relative Strength Index (RSI)
- JWEL 47.86
- PALI 51.35
- Support Level
- JWEL $1.90
- PALI $0.67
- Resistance Level
- JWEL $2.18
- PALI $0.86
- Average True Range (ATR)
- JWEL 0.13
- PALI 0.08
- MACD
- JWEL -0.02
- PALI 0.00
- Stochastic Oscillator
- JWEL 24.34
- PALI 32.56
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.